A single-blind randomized controlled trial comparing Aprepitant plus (Granisetron)1st 5-HT3 receptor antagonist and Palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies including CBDCA in the gynecology cancer patients. - A single-blind randomized controlled trial for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in the gynecology cancer patients.

St. Mariannna University, School of Medicine0 个研究点目标入组 300 人开始时间: 2012年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients complicated with serious hepatic disorders or renal disorders. 2. Patients with nausea and vomiting within 24 hours before initiation of cancer chemotherapy. 3. Patients who used an antiemetic agent within 48 hours before initiation of cancer treatment. 4. Patients with nausea and vomiting due to causes (brain tumor, digestive passage disorders, active peptic ulcer, brain metastasis, use of opioids, etc.) other than cancer chemotherapy. 5. Patients with an associated disease, including uncontrolled diabetes, that prevents administration of dexamethasone for three days. 6. Patients under medication with pimozide. 7. Patients for whom abdominal radiotherapy is planned. 8. Patients with a history of vomiting in past chemotherapy. 9. Patients judged to be inappropriate for the study by the physician in charge.

发起方